Special Report: Undaunted by challenging global circumstances, medical cannabis company Creso Pharma has sent its first shipment to South Africa.

Creso Pharma (ASX:CPH) has shipped the first order of its ‘cannaQIX® regular’ product to South African pharmaceutical company Pharma Dynamics, which will be launching it in South Africa.

Pharma Dynamics is a leading pharmaceutical company in South Africa, a subsidiary of Lupin (NSE:LUPIN), and is ranked the fifth biggest generic pharmaceutical company in SA.

It will be launching the Creso product under the brand name “Cannamics” in the second quarter of fiscal 2020.

“We are very excited to have completed the first delivery of cannaQIX® regular to Pharma Dynamics in South Africa,” Dr Miri Halperin Wernli, co-founder and CEO of Creso Pharma, said.

“We are delighted that customers in South Africa will be able to access our affordable, high-quality, hemp oil based GMP nutraceutical products from Q2 2020 onwards and we look forward to being able to broaden this distribution into additional countries through Africa.”

Pharma Dynamics distributes high quality generics at affordable prices and is well known for its investments in innovative wellness programs focusing on holistic healthcare.

Its growing range of over-the-counter products include cold and flu, allergy, heartburn and immune booster products. Their products are consistently prescribed and recommended by leading doctors and pharmacists countrywide.

cannaQIX range developed to help manage stress

The cannaQIX® range of products use hemp-derived cannabidiol (CBD), which are oil-based nutraceuticals using Creso Pharma’s proprietary innovative delivery technology.

They contain broad spectrum organic hemp oil extract with CBD, and aim to manage stress and to support mental and nervous functions. 

cannaQIX® regular is sugar-free and contains no tetrahydrocannabinol (THC).

The standardised, user-friendly strength and formulation allows precise dosage control and Creso says the lozenges have a more palatable taste compared to oils.

The cannaQIX® range has been developed to Good Manufacturing Practice (GMP) standards and is produced in Switzerland by Creso Pharma’s partner, Swiss-based food and pharma development company Domaco Dr med Aufdermaur AG, to the highest Swiss quality with a “Swiss Made” label.

“We are very happy that in spite of the current challenging circumstances, and thanks to a collaborative effort, we managed to deliver this first shipment on time,” Carole Abel, Creso Pharma director commercial operations, said.

“We would like to specifically thank our manufacturing partner Dr med Aufdermaur AG (Domaco) for their continuous support, commitment and professionalism.”

This story was developed in collaboration with Creso Pharma, a Stockhead advertiser at the time of publishing. This story does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.